A mother's persistence helps revive an all-but-abandoned drug class and could aid her son and thousands of others with ...
Morning Overview on MSN
Once-controversial exon-skipping drugs return as hope for Duchenne
Exon-skipping therapies for Duchenne muscular dystrophy, a class of drugs that triggered fierce regulatory debate when they ...
NEW YORK, Feb. 12, 2026 /PRNewswire-PRWeb/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that ...
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping oligonucleotide for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon ...
You have full access to this article via your institution. Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding methyl-CpG ...
Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio NEW YORK, Feb. 12, 2026 /PRNewswire-PRWeb/ -- Hoth Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results